Showing 2021-2030 of 5771 results for "".
- Allergan Announces Positive Phase 3 Topline Results for Investigational Eye Drop for the Treatment of Presbyopiahttps://modernod.com/news/allergan-announces-positive-phase-3-topline-results-for-investigational-eye-drop-for-the-treatment-of-presbyopia/2478467/Allergan announced the phase 3 GEMINI 1 and 2 clinical trials evaluating the efficacy, safety, and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of symptoms associated with presbyopia, met their primary efficacy endpoint. In GEMINI 1,
- iVeena Announces Positive Topline Results of IVMED-80 Eye Drops for Keratoconushttps://modernod.com/news/iveena-announces-positive-topline-results-of-ivmed-80-eye-drops-for-keratoconus/2478466/iVeena has announced topline results of its recently completed phase 1/2a clinical trial, “A Randomized, Double-Masked, Trial of IVMED-80 Eyedrops for Treatment of Keratoconus.” The study objective was to determine whether a 6- or 16-week course of twice-daily IVMED-80 eyedrops (vs. placebo) coul
- Tarsus Pharmaceuticals Announces Closing of Initial Public Offeringhttps://modernod.com/news/tarsus-pharmaceuticals-announces-closing-of-initial-public-offering/2478442/Tarsus Pharmaceuticals announced the closing of its initial public offering of 6,325,000 shares of its common stock at a price to the public of $16.00 per share, which includes 825,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock. All of
- The Vision Council Announces Dates for the 2021 Virtual Executive Summit: January 26–28, 2021https://modernod.com/news/the-vision-council-announces-dates-for-the-2021-virtual-executive-summit-january-26-28-2021/2478440/The Vision Council today announces that the
- Allergan Announces Updates to Eye Care Optometric Professional Relations Teamhttps://modernod.com/news/allergan-announces-updates-to-eye-care-optometric-professional-relations-team/2478432/Allergan Eye Care announced the retirement of Dave Gibson, Associate VP of Consumer Eye Care and Customer Development, after 20 years of service. Since 2009, Mr. Gibson has led Allergan’s Optometric Professional Relations team and helped launch a variety of programs to support the optometry com
- STRAP Technologies Announces Device to Aid the Visually Impairedhttps://modernod.com/news/strap-technologies-announces-device-to-aid-the-visually-impaired/2478430/STRAP Technologies announced the creation of a hands-free device designed to be worn by the visually impaired to allow for more independence and mobility. STRAP is a wearable, hands-free device with an array of sensors that work by sending real-time information that detect obstacles at the
- Outlook Therapeutics Announces Initiation of Open-Label Safety Study of Lytenava for Wet AMDhttps://modernod.com/news/outlook-therapeutics-announces-initiation-of-open-label-safety-study-for-lytenava-for-wet-amd/2478410/Outlook Therapeutics announced the initiation and enrollment of the first patients in its planned supplemental open-label safety study evaluating ONS-5010/Lytenava (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (AMD) (NORSE THREE). The open-label safety study
- Nicox Announces Plans for NCX 4251 Phase 2 Trial in Blepharitishttps://modernod.com/news/nicox-announces-plans-for-ncx-4251-phase-2-trial-in-blepharitis/2478408/Nicox SA announced that the upcoming Mississippi phase 2 trial of its second clinical candidate, NCX 4251 0.1%, will be focused on acute exacerbations of blepharitis. If successful in meeting the primary endpoint for blepharitis previously agreed upon with the FDA, the trial could represent the f
- UNITY Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edemahttps://modernod.com/news/unity-biotechnology-announces-first-patient-dosed-in-phase-1-study-of-ubx1325-in-diabetic-macular-edema/2478402/UNITY Biotechnology announced that the first patient has been dosed in a phase 1 study of UBX1325 in patients with diabetic macular edema (DME). “There is strong evidence of association between disease progression in DME and accumulation of senescent cells. There’s additional
- Santen and Orbis International Announce Long-term Partnership to Tackle the Increasing Burden of Eye Diseaseshttps://modernod.com/news/santen-and-orbis-international-announce-long-term-partnership-to-tackle-the-increasing-burden-of-eye-diseases/2478388/Santen Pharmaceutical and Orbis International announced a long-term, 10-year partnership aimed at addressing the increasing burden of eye diseases in low- and middle-income countries, especially in Asia. Under this long-term partnership, Santen and Orbis will acce